Your browser doesn't support javascript.
loading
Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples.
Khalsa, Jasneet Kaur; Cha, Justin; Utro, Filippo; Naeem, Aishath; Murali, Ishwarya; Kuang, Yanan; Vasquez, Kevin; Li, Liang; Tyekucheva, Svitlana; Fernandes, Stacey M; Veronese, Lauren; Guieze, Romain; Sasi, Binu Kandathilparambil; Wang, Zixu; Machado, John-Hanson; Bai, Harrison; Alasfour, Maryam; Rhrissorrakrai, Kahn; Levovitz, Chaya; Danysh, Brian P; Slowik, Kara; Jacobs, Raquel A; Davids, Matthew S; Paweletz, Cloud P; Leshchiner, Ignaty; Parida, Laxmi; Getz, Gad; Brown, Jennifer R.
Affiliation
  • Khalsa JK; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Cha J; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.
  • Utro F; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.
  • Naeem A; IBM Research, Yorktown Heights, New York, NY.
  • Murali I; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Kuang Y; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.
  • Vasquez K; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Li L; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.
  • Tyekucheva S; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA.
  • Fernandes SM; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA.
  • Veronese L; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.
  • Guieze R; Department of Data Sciences, Dana-Farber Cancer Institute, Harvard TH Chan School of Public Health, Boston, MA.
  • Sasi BK; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Wang Z; Service de Cytogénétique Médicale, CHU Clermont-Ferrand, Clermont-Ferrand, France.
  • Machado JH; EA7453 CHELTER, Université Clermont Auvergne, Clermont-Ferrand, France.
  • Bai H; EA7453 CHELTER, Université Clermont Auvergne, Clermont-Ferrand, France.
  • Alasfour M; Service d'Hématologie clinique et thérapie cellulaire, CHU Clermont-Ferrand, Clermont-Ferrand, France.
  • Rhrissorrakrai K; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Levovitz C; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.
  • Danysh BP; Department of Data Sciences, Dana-Farber Cancer Institute, Harvard TH Chan School of Public Health, Boston, MA.
  • Slowik K; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Jacobs RA; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.
  • Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Paweletz CP; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Leshchiner I; IBM Research, Yorktown Heights, New York, NY.
  • Parida L; IBM Research, Yorktown Heights, New York, NY.
  • Getz G; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.
  • Brown JR; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.
Blood ; 142(5): 421-433, 2023 08 03.
Article in En | MEDLINE | ID: mdl-37146250
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Leukemia, Lymphocytic, Chronic, B-Cell / Antineoplastic Agents Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Blood Year: 2023 Type: Article Affiliation country: Morocco
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Leukemia, Lymphocytic, Chronic, B-Cell / Antineoplastic Agents Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Blood Year: 2023 Type: Article Affiliation country: Morocco